Last reviewed · How we verify
Atorvastatin A
Atorvastatin A, marketed by Hanmi Pharmaceutical Company Limited, is a well-established drug in the lipid-lowering market. The key composition patent for Atorvastatin A is set to expire in 2028, providing a significant period of market exclusivity. The primary risk to the drug's market position is the potential increase in generic competition following the patent expiry.
At a glance
| Generic name | Atorvastatin A |
|---|---|
| Sponsor | Hanmi Pharmaceutical Company Limited |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Atorvastatin in Active Vitiligo (PHASE2)
- A Prospective, Open, Observational Study to Confirm the Lipid-lowering Effect, Changes in Glucose Metabolism, and Safety After 6 Months of Administration of Atostazet to Hypercholesterolemic Patients 65 Years of Age or Older
- A Study of Bempedoic Acid/Ezetimibe/High-intensity Statin in Patients Without Cardiovascular Events (PHASE3)
- Cholesterol Disruption in Combination With the Standard of Care in Patients With Advanced Pancreatic Adenocarcinoma (EARLY_PHASE1)
- Statin and Vitamin D Treatment in Patients With Thyroid Eye Disease (NA)
- Metformin Alleviates Abnormal Glucose Metabolism Induced by Statins in Schizophrenia Patients (PHASE3)
- Atorvastatin for Preventing Disease Metastasis in Patients With Resected High-Risk Stage IIA, IIB, or IIIA Melanoma (PHASE2)
- Moderate-intensity Statin vs. Individualized LDL-C Target-based Therapy in Older Adults With Type 2 Diabetes (iTARGET-Elderly Study) (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Atorvastatin A CI brief — competitive landscape report
- Atorvastatin A updates RSS · CI watch RSS
- Hanmi Pharmaceutical Company Limited portfolio CI